NASDAQ:HSDT Solana Q3 2024 Earnings Report $2.11 +0.25 (+13.44%) As of 08/21/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Solana EPS ResultsActual EPS-$742.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASolana Revenue ResultsActual Revenue$0.05 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASolana Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time4:00PM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Solana Earnings HeadlinesSolana Company Announces Voting Positions on First Three Solana Governance ProposalsAugust 21 at 11:10 AM | quiverquant.comQSolana Company Announces Positions and Votes on first Solana Governance ProposalsAugust 21 at 11:00 AM | globenewswire.comBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical. | TradeSmith (Ad)Solana Company (HSDT) Stock Earnings Call Transcripts - Yahoo FinanceAugust 20 at 8:51 AM | finance.yahoo.comB. Riley Financial Lowers Solana (NASDAQ:HSDT) Price Target to $2.50August 19 at 1:36 AM | americanbankingnews.comSolana Company Q2 Loss Hits $30.3 Million as SOL Treasury SuffersAugust 15, 2026 | finance.yahoo.comSee More Solana Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Solana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solana and other key companies, straight to your email. Email Address About SolanaHelius Medical Technologies, Inc. (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions. The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics. Frameworks of care vary by region but typically involve coordinated therapy protocols that combine the wearable stimulator, physical exercises and clinician-led monitoring. Helius supports its clinical users with training, device management and remote patient engagement tools to optimize rehabilitation outcomes. Beyond its core PoNS offering, Helius is advancing an at-home digital therapy program that integrates software-guided exercises and telehealth support. The company collaborates with research institutions and rehabilitation centers to broaden the evidence base for its technology and explore applications in conditions such as mild traumatic brain injury, multiple sclerosis and stroke recovery. Ongoing clinical studies aim to expand indications and refine therapy protocols. Founded in 2015 and headquartered in Toronto, Ontario, Helius Medical Technologies is led by President and Chief Executive Officer Dan M. Toutant. Since its inception, the company has pursued regulatory clearances across key markets and built partnerships with rehabilitation specialists to bring neuromodulation therapies to patients worldwide.View Solana ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx MissMicrosoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?Advance Auto Parts Plunged, But Its Turnaround Is Still WorkingWalmart's Post-Earnings Drop Could Be a Buying Opportunity3 Energy Stocks Raising Dividends as the Sector Surges5 Reasons the S&P 500 Could Keep Rallying Through Year-End Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
